News | August 18, 2010

Gold Helps Detect High-Risk Cardiovascular Disease

August 18, 2010 - Researchers from Mount Sinai School of Medicine have for the first time developed a way to visualize coronary artery plaques vulnerable to rupture using multicolor computed tomography (CT), an innovation that may lead to better and earlier diagnosis of cardiovascular disease.

The data are published in the September issue of Radiology.

Ruptures of atherosclerotic plaques are the cause of nearly 70 percent of heart attacks. High-density lipoproteins (HDL), the “good” cholesterol, are drawn to plaques vulnerable to rupture and remove them from the arterial wall.

The Mount Sinai team harnessed HDL by encapsulating tiny gold particles within it and injected them into mice. By using a sophisticated multicolor CT scanner, the researchers were able to see the gold particles as the HDL was targeting macrophages, or the cells that cause inflammation in the arterial wall, therefore illuminating the location of the vulnerable plaques.

“The use of multicolor CT and gold nanoparticles to visualize plaque will revolutionize cardiac imaging,” said the research team leader, Zahi A. Fayad, Ph.D., professor of radiology and medicine and the director of the Translational and Molecular Imaging Institute at Mount Sinai School of Medicine. “The acquisition of this technology and development of this method will help us improve cardiovascular disease diagnosis in our patients, furthering our commitment to translational research. We look forward to continuing our study of this technology in the clinical setting.”

In addition to showing the impact of the gold particles, spectral CT can simultaneously distinguish calcium deposits and contrast agents used such as iodine, which is often used to identify stenoses, or the narrowing of arteries, informing the severity of atherosclerosis and heart attack risk.

“There is a significant unmet need for imaging technology that visualizes plaque vulnerable to rupture,” said the lead author of the work, David Cormode, Ph.D., postdoctoral fellow, Translational and Molecular Imaging Institute, Mount Sinai School of Medicine. “The fact that the multicolor CT technique shows the gold particles, iodine and calcifications, provides us with a more complete picture of the nature of the atherosclerotic arteries.”

Multicolor CT technology may also be beneficial in imaging other biological process and diseases, including cancer, kidney disease, and bowel diseases. The Mount Sinai team plans to continue studying the new scanner in additional animal studies and in humans.

For more information: www.mountsinai.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now